Hui Zhang1, Ryu Watanabe1, Gerald J Berry2, Lu Tian3, Jörg J Goronzy1, Cornelia M Weyand4. 1. Department of Medicine, Division of Immunology and Rheumatology (H.Z., R.W., J.J.G., C.M.W.). 2. Department of Pathology (G.J.B.). 3. Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Stanford, CA. 4. Department of Medicine, Division of Immunology and Rheumatology (H.Z., R.W., J.J.G., C.M.W.) cweyand@stanford.edu.
Abstract
BACKGROUND: Giant cell arteritis, a chronic autoimmune disease of the aorta and its large branches, is complicated by aneurysm formation, dissection, and arterial occlusions. Arterial wall dendritic cells attract CD4+ T cells and macrophages to form prototypic granulomatous infiltrates. Vasculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering vasculitis. Transmural inflammation induces microvascular neoangiogenesis and results in lumen-occlusive intimal hyperplasia. We have examined whether persistent vessel wall inflammation is maintained by lesional T cells, including the newly identified tissue-resident memory T cells, and whether such T cells are sensitive to the cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1. METHODS: Vascular inflammation was induced in human arteries engrafted into immunodeficient mice that were reconstituted with T cells and monocytes from patients with giant cell arteritis. Mice carrying inflamed human arteries were treated with tofacitinib or vehicle. Vasculitic arteries were examined for gene expression (reverse transcription polymerase chain reaction), protein expression (immunohistochemistry), and infiltrating cell populations (flow cytometry). RESULTS: Tofacitinib effectively suppressed innate and adaptive immunity in the vessel wall. Lesional T cells responded to tofacitinib with reduced proliferation rates (<10%) and minimal production of the effector molecules interferon-γ, interleukin-17, and interleukin-21. Tofacitinib disrupted adventitial microvascular angiogenesis, reduced outgrowth of hyperplastic intima, and minimized CD4+CD103+ tissue-resident memory T cells. CONCLUSIONS: Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflammation of medium and large arteries. The JAK inhibitor tofacitinib effectively suppresses tissue-resident memory T cells and inhibits core vasculitogenic effector pathways.
BACKGROUND:Giant cell arteritis, a chronic autoimmune disease of the aorta and its large branches, is complicated by aneurysm formation, dissection, and arterial occlusions. Arterial wall dendritic cells attract CD4+ T cells and macrophages to form prototypic granulomatous infiltrates. Vasculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering vasculitis. Transmural inflammation induces microvascular neoangiogenesis and results in lumen-occlusive intimal hyperplasia. We have examined whether persistent vessel wall inflammation is maintained by lesional T cells, including the newly identified tissue-resident memory T cells, and whether such T cells are sensitive to the cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1. METHODS:Vascular inflammation was induced in human arteries engrafted into immunodeficientmice that were reconstituted with T cells and monocytes from patients with giant cell arteritis. Mice carrying inflamed human arteries were treated with tofacitinib or vehicle. Vasculitic arteries were examined for gene expression (reverse transcription polymerase chain reaction), protein expression (immunohistochemistry), and infiltrating cell populations (flow cytometry). RESULTS:Tofacitinib effectively suppressed innate and adaptive immunity in the vessel wall. Lesional T cells responded to tofacitinib with reduced proliferation rates (<10%) and minimal production of the effector molecules interferon-γ, interleukin-17, and interleukin-21. Tofacitinib disrupted adventitial microvascular angiogenesis, reduced outgrowth of hyperplastic intima, and minimized CD4+CD103+ tissue-resident memory T cells. CONCLUSIONS: Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflammation of medium and large arteries. The JAK inhibitor tofacitinib effectively suppresses tissue-resident memory T cells and inhibits core vasculitogenic effector pathways.
Authors: John J O'Shea; Daniella M Schwartz; Alejandro V Villarino; Massimo Gadina; Iain B McInnes; Arian Laurence Journal: Annu Rev Med Date: 2015 Impact factor: 13.739
Authors: Zhen Yang; Yi Shen; Hisashi Oishi; Eric L Matteson; Lu Tian; Jörg J Goronzy; Cornelia M Weyand Journal: Sci Transl Med Date: 2016-03-23 Impact factor: 17.956
Authors: Joseph J Maleszewski; Brian R Younge; John T Fritzlen; Gene G Hunder; Jorg J Goronzy; Kenneth J Warrington; Cornelia M Weyand Journal: Mod Pathol Date: 2017-03-03 Impact factor: 7.842
Authors: Ryu Watanabe; Toshihisa Maeda; Hui Zhang; Gerald J Berry; Markus Zeisbrich; Robert Brockett; Andrew E Greenstein; Lu Tian; Jörg J Goronzy; Cornelia M Weyand Journal: Circ Res Date: 2018-08-31 Impact factor: 17.367
Authors: Ryu Watanabe; Marc Hilhorst; Hui Zhang; Markus Zeisbrich; Gerald J Berry; Barbara B Wallis; David G Harrison; John C Giacomini; Jörg J Goronzy; Cornelia M Weyand Journal: JCI Insight Date: 2018-10-18